Metabolic Genetic Testing Market Analysis

The market for global metabolic genetic testing market is segmented by technique, out of which, over the projected period, the next-generation sequencing segment is expected to hold the highest share. The NGS market is expanding as a result of a number of factors, including ongoing technological advancements in sequencers and the widespread adoption of NGS technologies owing to their low cost and high efficiency. For instance, DNA Script is enabling their partners to explore the combined use of enzymatic synthesis of DNA and next-generation sequencing to enable accurate and low-cost decoding an important step to transitioning from digital to biology-based data storage.

Our in-depth analysis of the global metabolic genetic testing market includes the following segments:

By Technique

Next Generation Sequencing
Multiplex Ligation-dependent Probe Amplification (MLPA)
Amniocentesis
Others

By Indication

Amino Acid Metabolism Disorders
Carbohydrate Metabolism Disorders
Fatty Acid Metabolism Disorders
Purine and Pyrimidine Metabolism Disorders

By End User

Hospitals
Specialty Clinics
Academic and Research Institutes
Sports Training Centers
Others

Frequently Asked Questions (FAQ)

The metabolic genetic testing industry size is expected to expand at around 8.1% CAGR during the forecast period i.e., between 2024-2036.

The market growth is due to prevalence of various metabolic genetic disorders. The change in lifestyle during the previous years have led to increase in the risk of genetic metabolic diseases.

North America industry is estimated to dominate majority revenue share by 2036, as the region has major manufacturing and laboratories companies, and an increase in investments in new techniques.

The major players in the market include centogene NV, MedGenome, Blueprint Genetics Oy, Invitae Corporation, Quest Diagnostics, Orig3n, Bionano Genomics, Devyser, Laboratory Corporation of America, MyMedLab among others.

Metabolic Genetic Testing Market Analysis